

Diagnosis and Treatment of Type 2 Diabetes in Adults

A Review

Rita R. Kalyani, MD, MHS; Joshua J. Neumiller, PharmD, CDCES; Nisa M. Maruthur, MD, MHS; Deborah J. Wexler, MD, MSc

IMPORTANCE Type 2 diabetes involves progressive loss of insulin secretion from pancreatic β cells in the setting of insulin resistance and manifests clinically as hyperglycemia. Type 2 diabetes accounts for 90% to 95% of all cases of diabetes globally, with estimates ranging from 589 million to 828 million people worldwide. In the US, type 2 diabetes affects approximately 1 in 6 adults.

OBSERVATIONS Risk factors for type 2 diabetes include older age, family history, overweight or obesity, physical inactivity, gestational diabetes, Hispanic ethnicity, and American Indian or Alaska Native, Asian, or Black race. Diabetes is diagnosed if fasting plasma glucose is greater than or equal to 126 mg/dL, hemoglobin A_{1c} is greater than or equal to 6.5%, or 2-hour glucose during 75-g oral glucose tolerance testing is greater than or equal to 200 mg/dL. Approximately one-third of adults with type 2 diabetes have cardiovascular disease and 10.1% have severe vision difficulty or blindness. The prevalence of type 2 diabetes is 39.2% among patients with kidney failure. Although weight management is an important component of treatment for type 2 diabetes, no specific diet has been proven to be most effective for improving health outcomes. Physical activity can reduce hemoglobin A_{1c} by 0.4% to 1.0% and improve cardiovascular risk factors (ie, hypertension and dyslipidemia). Randomized clinical trials have reported absolute reductions in microvascular disease (3.5%), such as retinopathy and nephropathy, myocardial infarction (3.3%-6.2%), and mortality (2.7%-4.9%), with intensive glucose-lowering strategies (hemoglobin A_{1c} <7%) vs conventional treatment 2 decades after trial completion. First-line medications for type 2 diabetes include metformin and, in patients with cardiovascular or kidney comorbidities or at high cardiovascular risk, glucagon-like peptide-1 receptor agonists (GLP-1RAs) or sodium-glucose cotransporter 2 inhibitors (SGLT2is). Common add-on medications include dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs, dipeptidyl peptidase-4 inhibitors, sulfonylureas, and thiazolidinediones. Approximately one-third of patients with type 2 diabetes require treatment with insulin during their lifetime. Several randomized clinical trials have demonstrated benefits of specific SGLT2i and GLP-1RA medications compared with placebo for atherosclerotic cardiovascular disease (12%-26% risk reduction), heart failure (18%-25% risk reduction), and kidney disease (24%-39% risk reduction) over 2 to 5 years. Most trial participants with type 2 diabetes were taking metformin. High-potency GLP-1RA and dual GIP/GLP-1RA medications result in weight loss of greater than 5% in most individuals with type 2 diabetes, and weight loss may exceed 10%.

CONCLUSIONS Type 2 diabetes affects up to 14% of the global population and is associated with preventable long-term complications, such as cardiovascular disease, kidney failure, vision loss, and increased mortality. In addition to lifestyle modifications including diet, exercise, and weight management, metformin is generally first-line therapy for attainment of hemoglobin A_{1c} targets. For individuals with type 2 diabetes and cardiovascular or kidney disease or at high cardiovascular risk, guidelines recommend early treatment with SGLT2i and/or GLP-1RA medications.

JAMA. doi:10.1001/jama.2025.5956
Published online June 23, 2025.

-  [Multimedia](#)
-  [Supplemental content](#)
-  [CME at \[jamacmelookup.com\]\(https://jamacmelookup.com\)](#)

Author Affiliations: Division of Endocrinology, Diabetes, and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, Maryland (Kalyani); College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane (Neumiller); Division of General Internal Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland (Maruthur); Diabetes Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (Wexler).

Corresponding Author: Rita R. Kalyani, MD, MHS, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, 1830 E Monument St, Ste 333, Baltimore, MD 21287 (rrastogi@jhmi.edu).

The number of people with diabetes worldwide was estimated to be between 589 million and 828 million during 2022 to 2024,^{1,2} with type 2 diabetes comprising 90% to 95% of cases.^{1,3,4} Insulin resistance may be present for 10 years or longer prior to diagnosis.⁵ Although the global prevalence is rising (estimates range from 11%-14% of adult population), the incidence of type 2 diabetes has stabilized or decreased in most places worldwide.^{6,7} The prevalence of diabetes in US adults is 15.8%.⁴ In individuals with prediabetes, type 2 diabetes can be prevented or delayed with changes in health behaviors that lead to weight loss or pharmacotherapy.⁸

Risk factors for type 2 diabetes include overweight and obesity, physical inactivity, age, family history, race and ethnicity, history of gestational diabetes, and presence of other conditions (eg, hypertension, dyslipidemia, cardiovascular disease).⁹⁻¹⁴ More than 600 genetic variants are associated with an increased risk of type 2 diabetes.¹⁵ Although body mass index has a stronger association with type 2 diabetes than genetic risk scores,¹⁶ approximately 10% of individuals with type 2 diabetes do not have overweight or obesity.³

Globally, 32.2% of people with type 2 diabetes have cardiovascular disease.¹⁷ In the US, 1 in 10 individuals with diabetes have severe vision loss or blindness.³ Diabetes is a leading cause of kidney failure, nontraumatic lower extremity amputation, and death (30.4 deaths per 100 000 population).^{3,18} Diabetes-related comorbidities also include metabolic dysfunction-associated steatotic liver disease,¹⁹ cancers such as colorectal and breast,²⁰ and dementia.²¹ (eFigure 1 in the [Supplement](#)).^{20,21}

Although hemoglobin A_{1c} (HbA_{1c}) lowering with medications such as metformin and treatment of cardiovascular risk factors such as hypertension and hyperlipidemia are important,¹⁴ the availability of newer glucose-lowering drugs (glucagon-like peptide-1 receptor agonists [GLP-1RAs] and sodium-glucose cotransporter 2 inhibitor [SGLT2i] medications) that have cardiovascular, kidney, and weight loss benefits has led to changes in diabetes care recommendations. This review summarizes current evidence regarding the diagnosis and treatment of people with type 2 diabetes (**Box 1**).

Methods

We searched PubMed for English-language articles published within 5 years before and through June 12, 2024, and updated the search for additional articles published through February 14, 2025, using title keywords for diagnosis and treatment of type 2 diabetes ([Supplement](#)). We focused on high-quality studies and supplemented our search by identifying additional articles from references of selected articles and reviewed relevant current practice guidelines.

Of 2016 articles identified, 126 were included, consisting of 47 randomized clinical trials, 22 observational studies, 21 systematic reviews and/or meta-analyses, 21 guidelines, 12 narrative reviews, and 3 drug or device reference guides.

Units of Measure

We report laboratory values primarily in conventional units. To convert glucose from mg/dL to mmol/L, multiply values by 0.0555. To convert HbA_{1c} to mmol/mol, use the following equation: $(10.93 \times \text{HbA}_{1c}) - 23.50$.

Box 1. Commonly Asked Questions About Type 2 Diabetes

What tests can be used to diagnose type 2 diabetes?

Any of the following blood tests may be used to diagnose type 2 diabetes: fasting plasma glucose, 2-hour plasma glucose during a 75-g oral glucose tolerance test, or hemoglobin A_{1c} (HbA_{1c}). For routine screening, fasting plasma glucose and HbA_{1c} are typically preferred, although, the 2-hour plasma glucose is a more sensitive test and may help identify individuals who might otherwise not be identified as having diabetes using the other tests (ie, cystic fibrosis-related diabetes or post-transplantation diabetes).

Is metformin still first-line treatment for type 2 diabetes?

Many guidelines continue to recommend metformin as first-line treatment for type 2 diabetes. However, most guidelines now recommend that patients with type 2 diabetes and atherosclerotic cardiovascular disease, heart failure, or kidney disease receive treatment with sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists (GLP-1RAs) prior to or concurrently with metformin due to the decreased risk of disease progression with use of these medications.

When should injectable medications for type 2 diabetes be started?

For individuals with hyperglycemia despite use of metformin or other oral glucose-lowering agents, a GLP-1RA or dual glucose-dependent insulinotropic polypeptide/GLP-1RA is initially preferred over insulin per some guidelines for people with type 2 diabetes due to decreased hypoglycemia and increased weight loss. However, patients with severe hyperglycemic symptoms (ie, polyuria or polydipsia), unexpected weight loss, and/or HbA_{1c} >10% usually require treatment with insulin.

Diagnosis

Diabetes becomes clinically evident when elevated blood glucose levels cause glycosuria with resultant polyuria, polydipsia, fatigue, blurry vision, and unintentional weight loss. However, most individuals with type 2 diabetes are asymptomatic at diagnosis, and routine screening is recommended (**Box 2**).^{14,22}

The cut points recommended by the American Diabetes Association and World Health Organization for diagnosis of diabetes in nonpregnant adults are HbA_{1c} greater than or equal to 6.5%, fasting plasma glucose greater than or equal to 126 mg/dL after 8 hours of no caloric intake, 2-hour plasma glucose greater than or equal to 200 mg/dL during 75-g oral glucose tolerance testing, or unequivocal hyperglycemia including classic symptoms of hyperglycemia or life-threatening hyperglycemic crisis (ie, diabetic ketoacidosis or hyperosmolar hyperglycemic state) and random plasma glucose level greater than or equal to 200 mg/dL.^{14,23} Diagnosis requires 2 test results above the diagnostic threshold obtained at the same time (eg, HbA_{1c} and fasting plasma glucose) or at 2 different times, which may be either a repeat of the initial test or a different test.

HbA_{1c} is an indirect measure of glucose exposure from nonenzymatic glycation of hemoglobin and represents a weighted mean plasma glucose over the lifespan of the red blood cell, usually 2 to 3 months. HbA_{1c} generally has greater reliability than glucose levels, but may not accurately reflect time-averaged glucose levels in individuals with some hemoglobinopathies, pregnancy, HIV, recent blood transfusion, iron deficiency anemia, hemodialysis, or hemolytic

anemia.^{14,23} For these individuals, plasma glucose criteria are recommended for diagnosis. Recent physical activity, illness, or acute stress can raise or lower fasting glucose levels. The 2-hour plasma glucose level is more sensitive for diagnosis than fasting glucose or HbA_{1c} in identifying individuals with diabetes, and is the preferred test to diagnose cystic fibrosis-related diabetes or posttransplant diabetes; however, it is more cumbersome to perform and has greater day-to-day variability.¹⁴

Adult-onset type 1 diabetes and other types of diabetes, such as monogenic diabetes syndromes or diabetes secondary to medical conditions such as pancreatitis, may be misdiagnosed as type 2 diabetes, which can potentially delay initiation of appropriate treatment.²⁴ In adults with suspected type 1 diabetes (eg, body mass index <25, age <35 years, strong personal or family history of autoimmunity), testing with islet autoantibodies (initially glutamic acid decarboxylase and, if results are negative, then islet tyrosine phosphatase 2, zinc transporter 8, and/or insulin autoantibodies) can help identify type 1 diabetes.¹⁴ Clinical history and additional tests can help differentiate type 2 diabetes from other types of diabetes (Table 1).

Management

Health Behaviors

Weight management, including dietary modifications, is a fundamental component of diabetes treatment. However, no specific diet has been proven most effective for improving HbA_{1c}, weight loss, or health outcomes. In meta-analyses of people with diabetes (type 1 and 2), clinically meaningful HbA_{1c} reductions have been reported for Mediterranean-style vs control diets (difference in HbA_{1c}, -0.39% [95% CI, -0.58% to -0.20%]), the Dietary Approaches to Stop Hypertension vs control diets (difference in HbA_{1c}, -0.53% [95% CI, -0.62% to -0.43%]), and low- vs high-carbohydrate diets (difference in HbA_{1c} at 6 mo, -0.36% [95% CI, -0.62% to -0.09%]).²⁵⁻²⁷ In a trial of 7447 participants in Spain at high cardiovascular risk (50% with diabetes), the 5-year absolute risk of the cardiovascular primary end point (myocardial infarction, stroke, or death from cardiovascular causes) was 3.8% (95% CI, 3.2%-4.4%) in the group randomized to receive a Mediterranean diet combined with extra virgin olive oil or nuts vs 5.7% (95% CI, 4.6%-6.9%) in the control group (intention-to-treat hazard ratio, 0.70 [95% CI, 0.55-0.89]).²⁸

Medical nutrition therapy is individualized, in-depth nutrition therapy delivered by a registered dietitian. A systematic review of 18 randomized and nonrandomized clinical trials reported that medical nutrition therapy decreased HbA_{1c} among patients with type 2 diabetes by 0.3% to 2% at 6 months.^{29,30} Diabetes self-management education and support encompasses coping, diet, physical activity, medications, self-monitoring, complications, and problem-solving in diabetes.³¹ A meta-analysis of 20 randomized clinical trials comparing diabetes self-management education and support with usual care reported a pooled HbA_{1c} difference of -0.60% (95% CI, -0.85% to -0.35%).³² All types of physical activity, including aerobic and resistance, are beneficial for patients with type 2 diabetes.¹⁴ A meta-analysis of 126 randomized clinical trials (6718 patients) reported the optimal dose of physical activity for people with type 2 diabetes was 1100 metabolic-equivalent minutes per week (equivalent to approximately 244 minutes/week of

Box 2. Screening for Type 2 Diabetes

US Preventive Services Task Force

The US Preventive Services Task Force recommends screening for type 2 diabetes in adults aged 35 to 70 years who have overweight (body mass index [BMI] ≥25) or obesity (BMI ≥30) and that screening every 3 years may be reasonable for those with normal glucose levels.²²

American Diabetes Association

The American Diabetes Association recommends that all adults aged ≥35 years should be screened for type 2 diabetes at a minimum every 3 years. Adults of any age who have a history of gestational diabetes or who have overweight or obesity (BMI ≥25 or ≥23 in individuals of Asian ancestry) along with additional risk factors such as family history in a first-degree relative (ie, parent or sibling) are recommended to have screening every 1-3 years depending on risk status. Screening for type 2 diabetes is recommended yearly in individuals with prediabetes, defined by the American Diabetes Association as fasting plasma glucose 100-125 mg/dL, 2-hour plasma glucose during 75-g oral glucose tolerance test of 140-199 mg/dL, or hemoglobin A_{1c} of 5.7% to 6.4%.¹⁴

moderate-intensity aerobic physical activity). Dose-associated HbA_{1c} reductions with this level of activity ranged from 0.4% to 1.0%.³³

For persons with diabetes and overweight or obesity, American Diabetes Association guidelines recommend restriction of energy intake and increased energy expenditure (500-750 kcal/d energy deficit) to promote weight loss.¹⁴ The DiRECT Study, an open-label, cluster-randomized trial of 306 individuals from 49 primary care practices in the UK, reported that a very low-calorie formula diet (825-853 kcal/d) followed by stepped food reintroduction achieved remission of type 2 diabetes (HbA_{1c} <6.5% without diabetes medications for at least 2 months) among 46% of participants in the intervention group vs 4% in the control group at 12 months (odds ratio, 19.7 [95% CI, 7.8-49.8]).³⁴

The Action for Health in Diabetes (Look AHEAD) randomized clinical trial (including 5145 overweight persons with type 2 diabetes) reported that a long-term behavioral weight loss intervention including a goal of at least 175 minutes per week of moderate-intensity physical activity, compared with diabetes self-management education and support, resulted in no difference between groups for the primary cardiovascular outcome over a median of 9.6 years of follow-up. However, the weight loss intervention was associated with sustained weight loss, lower HbA_{1c}, delayed progression of kidney disease, and improvements in quality of life, depression, sleep apnea, urinary incontinence, and health care utilization and costs.³⁵

Glycemic Targets for Microvascular and Macrovascular Complications

Multiple trials have demonstrated that achieving an HbA_{1c} less than 7% in nonpregnant adults reduces the risk of microvascular complications such as retinopathy, neuropathy, and nephropathy.¹⁴ The UK Prospective Diabetes Study randomly assigned 4209 patients with newly diagnosed type 2 diabetes to receive conventional (primarily diet) vs intensive (insulin, sulfonylurea, or, if overweight, metformin) treatment, with mean attained HbA_{1c} of 7.9% vs 7.0%,

Table 1. Differentiating Type 2 Diabetes From Other Types of Diabetes in Nonpregnant Adults

Category	Type 2 diabetes	Type 1 diabetes	Monogenic diabetes syndromes (ie, MODY)	Types of diabetes secondary to other medical conditions
Epidemiology ^a	90%-95%	5%-10%	<5%	<5%
Pathophysiology	Nonautoimmune progressive loss of insulin secretion from β cells, usually in the setting of insulin resistance	Autoimmune β -cell destruction, usually leading to absolute or near-absolute insulin deficiency	Rare form of diabetes caused by a variant in a single gene disrupting β -cell glucose sensing or insulin production, inherited in an autosomal dominant manner; the most common forms are GCK-MODY (MODY2; glucose-sensing defect), HNF1A-MODY (MODY3), and HNF4A-MODY (MODY1)	Many different secondary forms of diabetes exist; examples include diseases of the exocrine pancreas (such as cystic fibrosis and pancreatitis), diabetes due to endocrinopathies such as Cushing syndrome or acromegaly, or diabetes secondary to SARS-CoV-2 infection
Age at diagnosis	Usually ≥ 35 y but increasingly seen in youth and younger adults, especially in the setting of obesity and/or family history	Can occur in adults at any age, often with more indolent onset compared with children (termed <i>latent autoimmune diabetes in adults</i>)	Usually <25 y	Any age
Degree of hyperglycemia on presentation	Usually mild (blood glucose <250 mg/dL) if detected early; however, can be moderate or severe in long-standing undiagnosed diabetes.	Usually moderate (blood glucose of 250-600 mg/dL); can be severe (blood glucose >600 mg/dL) in some cases	Mild; usually $HbA_{1c} < 7.5\%$ at diagnosis	Mild, moderate, or severe
Symptoms	Can be asymptomatic or with symptoms	Usually with catabolic symptoms (polyuria, polydipsia, weight loss); can be asymptomatic in adults	Usually asymptomatic	Can be asymptomatic or with symptoms
BMI	Usually BMI ≥ 25	Usually BMI <25, but can be diagnosed in those with overweight or obesity	Variable, but obesity usually not present	Any
Family history	Often a first-degree relative with type 2 diabetes, but not always	Sometimes a first-degree relative with type 1 diabetes or other autoimmune disease; 85% have no family history	Autosomal dominant family history, confirmed to be MODY diabetes	Not usually
Diabetic ketoacidosis	Can be seen on presentation in those with severe insulin deficiency or glucotoxicity (termed <i>ketosis-prone type 2 diabetes</i>); euglycemic diabetic ketoacidosis has been described in individuals taking SGLT2is	Ketoacidosis common on presentation in children; variable on presentation in adults	Unlikely	Rare; has been reported with SARS-CoV-2 infection and can occur with severe pancreatitis
Autoantibodies present	Not usually seen, but can be present in up to 10% of individuals, depending on the population	Common, but 5%-10% will not have antibodies present on diagnosis, and levels can wane over time; the following antibodies are often tested: glutamic acid decarboxylase (GAD), islet tyrosine phosphatase-related islet antigen 2 (IA-2), zinc transporter 8 (ZnT8) and/or insulin autoantibodies (IAA)	Unlikely	Unlikely
Race and ethnicity	Any; more common in Asian American and Pacific Islander, Black, Latino, and Native American individuals than White individuals	Any; more common with European ancestry	Any; most described in populations of European ancestry	Any
Genetic testing	Not commercially available	Not commercially available; currently only in research studies	Yes; required for definitive diagnosis	Not commercially available
Duration prior to diagnosis	Long (years)	Short (months)	Long (years; potentially lifelong undiagnosed in mild cases)	Variable
Stimulated C-peptide ^b	Detectable	Low or undetectable (<200 pmol/L); may be detectable soon after diagnosis or for prolonged duration in adult-onset	Detectable	Variable
Drugs that may exacerbate or contribute to development of diabetes	Long-term glucocorticoids, use of immunosuppressant drugs after organ transplant such as tacrolimus and cyclosporine (ie, new-onset diabetes after transplant), ^c and second-generation antipsychotics such as olanzapine and clozapine ^d	Immune checkpoint inhibitors such as nivolumab and pembrolizumab (for cancer)	None	Antiretroviral therapies (ie, certain protease inhibitors and nucleoside reverse transcriptase inhibitors) in people with HIV ^d ; glucocorticoid treatment with active COVID-19

(continued)

Table 1. Differentiating Type 2 Diabetes From Other Types of Diabetes in Nonpregnant Adults (continued)

Category	Type 2 diabetes	Type 1 diabetes	Monogenic diabetes syndromes (ie, MODY)	Types of diabetes secondary to other medical conditions
Related comorbidities	See eFigure 1 in the Supplement	Other autoimmune conditions	Associated features of a specific MODY type (eg, renal cysts, partial lipodystrophy, maternally inherited deafness, severe insulin resistance in the absence of obesity)	Depends on secondary medical condition
Treatment	Lifestyle change, oral agents, noninsulin injectables, insulin	Insulin	Depends on type; no treatment (GCK-MODY), sulfonylureas (HNF1A-MODY or HNF4A-MODY), sometimes insulin is needed	Variable, depends on secondary medical condition; DPP4i or GLP-1 less preferred in patients with pancreatitis

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); DPP4i, DPP-4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; MODY, maturity-onset diabetes of the young; SGLT2i, sodium-glucose cotransporter 2 inhibitor.

^a The exact prevalence of different types of diabetes may depend on the population; thus, ranges are provided for each type.

^b Refer to endocrinologist for testing; usually performed after stimulation with glucagon injection or mixed meal test. A C-peptide measurement (with simultaneous glucose) obtained within 5 hours of eating can replace a formal C-peptide stimulation test for classification.

^c Screen with oral glucose tolerance test after immunosuppressive regimen is stable.

^d Screen for prediabetes or diabetes at baseline when prescribed these drugs; repeat at 3 months, if clinically indicated, and annually.¹⁴

respectively.^{36,37} An observational study that published follow-up data (median of 17.5 years [range, 0-42 years]) on 1489 (97.6%) of the 1525 surviving participants reported reductions in all-cause mortality (2.7%-4.9%), myocardial infarction (3.3%-6.2%), and microvascular disease defined as vitreous hemorrhage, retinal photocoagulation, death due to kidney disease, or kidney failure (3.5%) in those previously randomized to receive intensive treatment vs conventional therapy ($P < .05$ for all comparisons).³⁸

ACCORD,³⁹ ADVANCE,⁴⁰ and VADT⁴¹ were trials of intensive vs standard glycemic control using oral glucose-lowering agents or insulin (conducted prior to availability of SGLT2is and GLP-1RAs) in participants with longer duration of type 2 diabetes (mean of 10 years); approximately one-third of participants in each trial had cardiovascular disease. ACCORD included 10 251 patients with type 2 diabetes; the intensive vs standard care group achieved mean HbA_{1c} of 6.4% (target <6%) vs 7.5%, respectively, at 1 year. ADVANCE enrolled 11 140 patients with type 2 diabetes and targeted HbA_{1c} less than or equal to 6.5% in the intensive group (mean HbA_{1c} of 6.5% in the intensive group vs 7.3% in the standard care group). VADT enrolled 1791 veterans with type 2 diabetes, targeting a difference in HbA_{1c} of 1.5% between the groups (mean HbA_{1c} of 6.9% in the intensive group vs 8.4% in the standard care group). Intensive control reduced retinopathy progression in ACCORD (7.3% vs 10.4%; $P = .003$)⁴² and incidence of nephropathy in ADVANCE (4.1% vs 5.2%; $P = .006$).⁴⁰ However, the only microvascular complication that showed a significant reduction among patients treated with intensive glycemic control in VADT was a decrease in worsening albuminuria.⁴¹

Although these studies demonstrate that more intensive glycemic targets (HbA_{1c} <6.5%) may benefit microvascular disease, these targets do not have consistent benefits for macrovascular disease, defined as nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death. In ACCORD, compared with the standard care group, the intensive glycemic control group had increased hypoglycemia (10.5% vs 3.5%; $P < .001$), weight gain greater than 10% (28% vs 14%; $P < .001$), and mortality (5% vs 4%; hazard ratio, 1.22 [95% CI, 1.01-1.46]), prompting early trial discontinuation.^{39,43} ADVANCE and VADT reported no significant differences between intensive glycemic control vs standard care on macrovascular outcomes during the trial periods.^{40,41} An observational study with 10-year follow-up of VADT participants reported an absolute risk reduction of 8.6 major cardiovascular events per 1000 person-years, although this benefit was no longer present at 15 years.⁴⁴

In a meta-analysis and systematic review of 15 randomized clinical trials and observational studies (783 255 patients) comparing intensive control (HbA_{1c} <7.5%) vs standard care in adults 60 years or older or frail adults of any age with type 2 diabetes, there was no difference in mortality, but intensive control was associated with both a reduction in microvascular and macrovascular complications and increased risk for severe hypoglycemia.⁴⁵ Older adults with cognitive or functional limitations and those with reduced life expectancy experience less benefit from intensive glycemic targets and more harm from overtreatment, including increased risk of severe hypoglycemia, which may lead to falls and fractures.⁴⁶

Glucose Monitoring

In addition to HbA_{1c} testing, ambulatory glucose monitoring with fingerstick blood glucose monitoring (BGM) and/or continuous

glucose monitoring (CGM) is important for achieving glycemic goals in many individuals with type 2 diabetes. Although BGM has not been demonstrated to decrease HbA_{1c} in type 2 diabetes not treated with insulin,⁴⁷ it can be considered to help some patients adjust lifestyle or medication regimens.¹⁴ (eFigure 2 in the [Supplement](#)). For patients only taking basal insulin, once-daily fasting BGM can suffice to achieve fasting glucose targets (80-130 mg/dL for many non-pregnant adults based on American Diabetes Association guidelines) and reduce HbA_{1c}.^{14,48}

A systematic review and meta-analysis of CGM use in adults with type 2 diabetes (12 randomized clinical trials with 1248 participants taking insulin, GLP-1RA, or oral glucose-lowering medications) reported that CGM led to a mean difference in HbA_{1c} reduction over 10 to 34 weeks of -0.31% (95% CI, -0.43% to -0.19%) compared with BGM.⁴⁹ In a randomized clinical trial of 224 participants with type 2 diabetes taking insulin, CGM decreased hypoglycemic episodes, reducing time with blood glucose less than 70 mg/dL by 0.47 hours per day compared with BGM.⁵⁰ CGM accuracy is slightly lower the first day following sensor insertion and when glucose levels are rapidly changing.⁵¹

For people taking multiple daily injections of insulin, evidence-based guidelines recommend BGM be performed at a minimum prior to meals and at bedtime to guide insulin dosing and avoid hypoglycemia, and that CGM be offered to all people with type 2 diabetes taking insulin and considered for those taking other noninsulin glucose-lowering therapies, with a goal of achieving greater than 70% of time in range (blood glucose of 70-180 mg/dL) for most nonpregnant adults.^{14,52,53}

Glucose-Lowering Medications for Type 2 Diabetes

The number of glucose-lowering medications for treatment of type 2 diabetes has increased over recent years with currently available therapies targeting different organs and sites of action that contribute to the development of hyperglycemia ([Figure](#)).⁵⁴

Initiation of glucose-lowering pharmacotherapy is associated with reduced long-term microvascular and macrovascular complications.^{36,37,55-83} Patients presenting with severe hyperglycemia symptoms such as polyuria and polydipsia, unexpected weight loss, or HbA_{1c} greater than 10% should initially be treated with insulin. In asymptomatic patients diagnosed with type 2 diabetes, most guidelines recommend metformin as the first medication in those without cardiovascular comorbidities (ie, atherosclerotic cardiovascular disease or heart failure) or chronic kidney disease. This recommendation is based on the high glycemic efficacy, low hypoglycemia risk, general tolerability, and low cost of metformin.⁸⁴ The major barrier to use of metformin is gastrointestinal adverse effects such as diarrhea ([Table 2](#)), which may be ameliorated by slow dose titration (eg, starting with 500 mg once daily followed by gradual dose escalation by 500 mg every week until target dose is reached)⁸⁹ or switching to an extended-release formulation. A meta-analysis of 15 randomized clinical trials (N = 3765) reported that extended-release metformin was associated with a nonsignificant reduction in gastrointestinal adverse effects compared with immediate-release metformin (24.6% vs 28.1%; odds ratio, 0.76 [95% CI, 0.58-1.00]).⁹⁰

A randomized trial of 5047 patients with type 2 diabetes who were taking metformin assigned patients to receive a sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist

(liraglutide), or basal insulin glargine. At 5 years of follow-up, the incidence of HbA_{1c} greater than 7.0% was lower with the addition of insulin glargine or liraglutide (26.5 and 26.1 per 100 participant-years, respectively) than glimepiride or sitagliptin (30.4 and 38.1 per 100 participant-years, respectively) ($P < .001$ for a global test of differences across all groups).⁹¹ Patients in the GLP-1RA group had more weight loss (mean, -3.5 kg). For individuals taking 1 or more oral glucose-lowering drugs at maximally tolerated doses who require injectable therapies to meet glycemic targets (ie, HbA_{1c} level more than 1.5%-2% above goal) in the absence of severe hyperglycemia symptoms, use of a GLP-1RA or dual GLP-1/GIP-RA is initially preferred to insulin due to decreased hypoglycemia and increased weight loss by many guidelines ([Table 3](#) and [Table 4](#)).¹⁴ Newer, high-potency weekly GLP-1RAs (ie, high-dose semaglutide or dulaglutide) and dual GIP/GLP-1RAs (ie, tirzepatide) are associated with mean HbA_{1c} reductions up to approximately 2% to 2.5% and weight reductions of greater than 5% from baseline in most individuals, with some exceeding 10%.⁸⁰

Insulin therapy is eventually required by up to one-third of adults with type 2 diabetes to maintain glycemic goals as β -cell function declines.^{14,103} A variety of insulin formulations with different onsets of action and durations of effect are available ([Table 3](#); [eFigure 3](#) in the [Supplement](#)).⁹² Basal insulin is the most common initially prescribed insulin in type 2 diabetes, with addition of insulin at meals as needed to target postprandial hyperglycemia (ie, 1-2 hours after the beginning of the meal) and achieve glycemic targets.¹⁴ Mixed insulin regimens can be administered individually (eg, separate basal and prandial injections) or as premixed (eg, 70/30) preparations, depending on patient preferences for injection frequency and need for dosing flexibility.⁹² For individuals requiring large doses of insulin due to high levels of insulin resistance, concentrated insulin products (ie, 2-5 times more insulin per unit volume) can reduce injection volume and discomfort ([Table 3](#)).

Insulin pumps are palm-sized devices that deliver rapid-acting insulin (ie, aspart or lispro) throughout the day through tubing and a cannula inserted under the skin or attached directly to the skin. In a randomized multicenter clinical trial of 319 patients over 13 weeks, use of an automated insulin pump paired with CGM and an algorithm to automatically adjust insulin delivery based on real-time glucose levels led to a mean HbA_{1c} reduction of -0.6% (95% CI, -0.8% to -0.4%; $P < .001$) compared with multiple daily injections of insulin and CGM alone.¹⁰⁴ Evidence-based guidelines recommend insulin pump therapy be offered to individuals with type 2 diabetes taking multiple daily injections of insulin who are capable of using these devices safely.^{14,52,53}


Comorbidity Considerations When Selecting Glucose-Lowering Medications

For people with type 2 diabetes who have established or are at high risk for atherosclerotic cardiovascular disease, heart failure (HF), or chronic kidney disease (CKD), evidence-based guidelines recommend SGLT2is or GLP-1RAs oftentimes irrespective of HbA_{1c} levels ([Table 4](#)).¹⁰⁵

Atherosclerotic Cardiovascular Disease

Specific SGLT2i^{61,62} and GLP-1RA⁷⁰⁻⁷² medications have demonstrated significant risk reductions for major adverse cardiovascular events in large trials that mostly enrolled participants with type 2

Figure. Key Pathophysiologic Defects in Type 2 Diabetes and Primary Sites of Action of Glucose-Lowering Medications



There are multiple pathophysiological defects in various organs that contribute to the development of hyperglycemia in type 2 diabetes.⁵⁴ Different classes of glucose-lowering medications are currently available, each with specific mechanisms of action to lower blood glucose that target these defects. Commonly used medication for type 2 diabetes are included. DPP-4i indicates

dipeptidyl peptidase-4 inhibitor; GIP/GLP-1RA, glucose-dependent insulinotropic polypeptide/ glucagon-like peptide-1 receptor agonist; GLP-1RA, glucagon-like peptide-1 receptor agonist; SGLT2i, sodium-glucose cotransporter 2 inhibitor.

diabetes and history of established cardiovascular diseases; more than 70% of participants were receiving background metformin therapy.¹⁰⁶ Trials with agents from the DPP-4 inhibitor class have generally established safety, but not cardiovascular benefit.¹⁴

A meta-analysis of 6 trials of 4 SGLT2 inhibitors, including 46 969 participants with type 2 diabetes (66% with established cardiovascular disease) with median follow-up from 2.4 to 4.2 years reported reduction in risk of the primary 3-point major adverse cardiovascular events outcome of myocardial infarction, stroke, or cardiovascular death (hazard ratio, 0.90 [95% CI, 0.85-0.95]). Significant reductions were also observed in secondary outcomes including cardiovascular death, hospitalization for heart failure, and kidney disease progression, defined as worsening estimated glomerular filtration rate (eGFR) or creatinine, kidney failure, death from renal causes, or cardiovascular death.¹⁰⁷

Similarly, a meta-analysis of 7 trials of 6 injectable GLP-1RAs and 1 oral GLP-1RA among 56 004 participants with type 2 diabetes (76% with established cardiovascular disease) over a median follow-up of 1.3 to 5.4 years reported a reduction in both the primary major adverse cardiovascular events outcome (10.5% with GLP-1RA treatment vs 11.8% with placebo; hazard ratio, 0.88 [95% CI, 0.82-0.94]) and secondary outcomes including a reduction in cardiovascular mortality (fatal or nonfatal stroke and fatal or nonfatal myocardial infarction).¹⁰⁸

Cardiovascular effects of glucose-lowering medications approved by the US Food and Drug Administration prior to 2008 have a weaker evidence base because large, randomized cardiovascular outcome trials were not mandated at the time; however, metformin and pioglitazone likely have cardiovascular benefit.^{60,104,105}

Table 2. Factors for Individualized Selection of Nonsulin Glucose-Lowering Medications in People With Type 2 Diabetes^a

Drug (glucose-lowering dose)	Glucose-lowering efficacy ^{5,5,6,8}	Impact on weight ^{3,6,5,7,8}	Hypoglycemia risk as monotherapy	Impact on comorbidities ^d	Cost ^{5,8,9}	Common adverse effects ^{5,9,9}	Practical considerations ^{5,9}
Alpha-glucosidase inhibitors: Acarbose (25–100 mg orally at each meal) Miglitol (25–100 mg orally at each meal)	Intermediate (0.5%)	Neutral	No	Atherosclerotic cardiovascular disease: neutral ⁶ HF ⁵ : neutral ^{6,5}	\$–\$\$\$	Most common adverse effects: abdominal pain (1.2%–1.9%), diarrhea (2.9%–3.1%), elevated transaminases (1.4% [acarbose]), flatulence (4.2%–7.4%) Contraindications: cirrhosis, inflammatory bowel disease, colonic ulceration, intestinal obstruction, hypersensitivity Warnings/precautions: hypoglycemia (add-on to sulfonylurea and/or insulin); use oral glucose (not sucrose) to treat hypoglycemia	When to use Add-on treatment in individuals who require intermediate levels of HbA _{1c} lowering (0.5%–1% above target); not as commonly used due to gastrointestinal adverse effects Can reduce postprandial hyperglycemia Dosing considerations: Take only when eating Start low dose, titrate slowly to minimize gastrointestinal adverse effects
Biguanides: Metformin (500–2000 mg orally daily)	High (1.0%–2.0%)	Neutral (potential for modest weight loss)	No	Atherosclerotic cardiovascular disease: likely long-term benefit ^{5,6,6} Chronic kidney disease: neutral HF: neutral	\$	Most common adverse effects ^b : diarrhea (1.0%–5.3%), nausea/vomiting (7%–26%), abdominal discomfort (1%–6%) Contraindications: estimated glomerular filtration rate <30 mL/min/1.73 m ² , acute or chronic metabolic acidosis, hypersensitivity Warnings/precautions: vitamin B12 deficiency, lactic acidosis	When to use First-line treatment when initial HbA _{1c} <9%–10% and in absence of life-threatening hyperglycemic crisis (ie, diabetic ketoacidosis or hyperosmolar hyperglycemic state) Can be used at reduced doses (ie, 1000 mg) with estimated glomerular filtration rate 30–45 mL/min/1.73 m ² If gastrointestinal symptoms develop Hold or reduce dose to assess the relationship of symptoms to metformin Consider switching to extended-release formulation Take with food to improve tolerability and/or continue at reduced dose When to hold Prior to procedure with nothing per mouth or illness Day of procedure Resume when eating normally
Dipeptidyl peptidase-4 inhibitors: Alogliptin (6.25–25 mg orally daily) Linagliptin (5 mg orally daily) Saxagliptin (2.5–5 mg orally daily) Sitagliptin (25–100 mg orally daily)	Intermediate (<0.5%)	Neutral	No	Atherosclerotic cardiovascular disease: neutral Chronic kidney disease: neutral HF: potential risk with saxagliptin ^{7,7}	\$–\$\$\$	Most common adverse effects: upper respiratory infection (4%–8%), nasopharyngitis (5%–7%), headache (4%–7%) Contraindications: hypersensitivity Warnings/precautions: pancreatitis, hypersensitivity reactions, arthralgia, bullous pemphigoid	When to use Add-on treatment in individuals who require intermediate levels of HbA _{1c} lowering (0.5%–1% above target) without risk of hypoglycemia For patients who desire to maintain weight Combination therapy: Dipeptidyl peptidase-4 inhibitors should not be combined with GLP-1RAs or dual GLP-1/GIP RAs because they act on the same pathway

(continued)

Table 2. Factors for Individualized Selection of Nonsulin Glucose-Lowering Medications in People With Type 2 Diabetes^a (continued)

Drug (glucose-lowering dose)	Glucose-lowering efficacy ^{3,5,6,6}	Impact on weight ^{3,6,7,c}	Hypoglycemia risk as monotherapy	Impact on comorbidities ^d	Cost ^{58,f}	Common adverse effects ^{59,g,e}	Practical considerations ⁵⁹
GLP/GLP-1RA: Tirzepatide (2.5-15 mg subcutaneously once weekly)	High (1.0%-2.0%) to very high (2.0%-2.5%)	Loss (high)	No	Atherosclerotic cardiovascular disease: safe ⁱ Chronic kidney disease: safe ⁱ HF: benefit in obesity-related HFpEF ¹⁰⁹	\$\$\$	Most common adverse effects: nausea (18%), diarrhea (17%), vomiting (9%), constipation (7%), dyspepsia (5%), abdominal pain (5%) Contraindications: personal or family history of medullary thyroid cancer or in patients with multiple endocrine neoplasia 2 Warnings/precautions: pancreatitis, hypoglycemia (add-on to sulfonylurea and/or insulin), diabetic retinopathy complications, acute kidney injury, hypersensitivity reactions, acute gallbladder disease	When to use Add-on treatment in individuals taking ≥1 oral glucose-lowering drugs at maximally tolerated doses who require high to very high levels of HbA _{1c} lowering (ie, HbA _{1c} >1.0%-2.5% above goal) Can be used for patients who desire substantial weight loss When to hold Prior to procedures, consider dietary adjustments (eg, liquid diet) or holding therapy (eg, day of procedure for daily formulations or 1 week prior for weekly formulations) in those at high risk for delayed gastric emptying When adding to insulin Reduce then stop prandial insulin Reduce the basal insulin dose as GLP-1 dose increases, guided by glucose monitoring
GLP-1RAs: Dulaglutide (0.75-4.5 mg subcutaneously once weekly) Exenatide extended release (2 mg subcutaneously once weekly) Liraglutide (0.6-1.8 mg subcutaneously daily) Semaglutide (0.25-2 mg subcutaneously once weekly or 3-14 mg orally daily or 1.5-9 mg orally daily)	High (1.0%-2.0%) to very high (2.0%-2.5%)	Loss (intermediate to high)	No	Atherosclerotic cardiovascular disease: benefit on major cardiovascular events with dulaglutide, ⁷⁰ liraglutide, ⁷¹ and semaglutide ^{72,86} Chronic kidney disease: benefit on progression with semaglutide (subcutaneous) ⁷³ HF: evidence of benefit in obesity-related HFpEF with semaglutide (subcutaneous) ^{74,75}	\$\$\$	Most common adverse effects: nausea (8%-21%), vomiting (3%-13%), diarrhea (9%-13%), abdominal pain (6%-11%), constipation (2%-5%) Contraindications: personal or family history of medullary thyroid cancer or in patients with multiple endocrine neoplasia 2 Warnings/precautions: pancreatitis, hypoglycemia (add-on to sulfonylurea and/or insulin), diabetic retinopathy complications, acute kidney injury, hypersensitivity reactions, acute gallbladder disease	When to use First-line treatment in atherosclerotic cardiovascular disease, chronic kidney disease, obesity-related HFpEF Add-on treatment in individuals without cardiovascular or kidney comorbidities taking 1 or more oral glucose-lowering drugs at maximally tolerated doses who require high to very high levels of HbA _{1c} lowering (ie, HbA _{1c} level >1.0%-2.5% above goal) Can be used for patients who desire moderate weight loss When to hold: Prior to procedures, consider dietary adjustments (eg, liquid diet) or holding therapy (eg, day of procedure for daily formulations or 1 week prior for weekly formulations) in those at high risk for delayed gastric emptying Switching GLP-1 formulations: Although there is no standard dose equivalence, the following may be used as a guide: semaglutide oral 14 mg ~ semaglutide subcutaneous 0.5 mg ~ dulaglutide 1.5 mg ~ liraglutide 1.8 mg ~ tirzepatide 2.5 mg ^{76,80} When adding to insulin: Reduce, then stop prandial insulin Reduce the basal insulin dose as GLP-1 dose increases, guided by glucose monitoring

(continued)

Table 2. Factors for Individualized Selection of Nonsulin Glucose-Lowering Medications in People With Type 2 Diabetes^a (continued)

Drug (glucose-lowering dose)	Glucose-lowering efficacy ^{3,5,6,b}	Impact on weight ^{3,6,7,c}	Hypoglycemia risk as monotherapy	Impact on comorbidities ^d	Cost ^{58,f}	Common adverse effects ^{59,g,e}	Practical considerations ⁵⁹
Meglitinides:							
Nateglinide (60-120 mg orally at each meal)	High (1%-2%)	Gain	Yes	Atherosclerotic cardiovascular disease: neutral ⁸⁷ HF: neutral ⁸⁷	\$	Most common adverse effects: hypoglycemia (up to 31%), upper respiratory infection (11%-16%), back pain (4%-5%), flu-like symptoms (4% [nateglinide]), arthropathy (3%-6%), diarrhea (3%-5%) Contraindications: hypersensitivity Warnings/precautions: hypoglycemia risk	When to use Add-on treatment in individuals who require high levels of HbA _{1c} lowering (1%-2% above target); not as commonly used due to multiple daily dosing and risk of hypoglycemia Can reduce postprandial hyperglycemia When to hold Hold day of procedure; resume when eating normally
SGLT2 inhibitors ⁴ :							
Bexagliflozin (20 mg orally daily)	Intermediate (0.5%)	Loss (intermediate)	No	Atherosclerotic cardiovascular disease: benefit on major cardiovascular events with canagliflozin ⁶¹ and empagliflozin ⁶² Chronic kidney disease: benefit on progression with canagliflozin, ⁶³ dapagliflozin, ⁶⁴ and empagliflozin ⁶⁵ HF: benefit in HFpEF and HFrEF with dapagliflozin ^{66,69,68} and empagliflozin ^{67,68}	\$-\$\$\$	Most common adverse effects: genital mycotic infections (6%-12%), urinary tract infection (4%-8%), increased urination (2%-7%) Contraindications: hypersensitivity Warnings/precaution: euglycemic diabetic ketoacidosis, volume depletion, severe urinary tract infections, hypoglycemia (add-on to sulfonylurea and/or insulin), Fournier gangrene; lower limb amputation, fractures with canagliflozin	When to use First-line treatment in atherosclerotic cardiovascular disease, chronic kidney disease, HF Add-on treatment in individuals without cardiovascular or kidney comorbidities who require intermediate levels of HbA _{1c} lowering (0.5%-1% above target) Can be used for patients who desire moderate weight loss When to hold Hold 3-4 d prior to procedures Consider holding if risk of dehydration (eg, religious fasting, strenuous exercise on hot day)
Dapagliflozin (5-10 mg orally daily)							
Empagliflozin (10-25 mg orally daily)							
Ertugliflozin (5-15 mg orally daily)							
Sulfonylureas:							
Glimepiride (1-8 mg orally daily)	High (1%-2%)	Gain	Yes	Atherosclerotic cardiovascular disease: neutral Chronic kidney disease: neutral HF: neutral	\$	Most common adverse effects (glimepiride) ⁶ : hypoglycemia (20%), headache (8%), nausea (5%), dizziness (5%) Contraindication: hypersensitivity Warnings/precautions: severe hypoglycemia risk, hemolytic anemia (glucose-6-phosphate dehydrogenase deficiency), special warning for increased risk of cardiovascular mortality based on studies with an older-generation sulfonylurea (tolbutamide); glimepiride demonstrated safety ⁶¹	When to use Add-on treatment in individuals who require high levels of HbA _{1c} lowering (1%-2% above target) Inexpensive and can be used when cost is a concern When to hold Day of procedure; resume when eating normally To minimize hypoglycemia In those at higher risk (eg, older adults, chronic kidney disease), do not use glyburide, which is longer-acting and associated with higher risk of hypoglycemia vs other sulfonylureas Glimepiride or glipizide are shorter-acting and preferred Dose cautiously; do not overtreat
Glipizide (IR: 2.5-40 mg orally daily; extended release: 2.5-20 mg orally daily)							
Glyburide (1.25-20 mg orally daily)							

(continued)

Table 2. Factors for Individualized Selection of Nonsulin Glucose-Lowering Medications in People With Type 2 Diabetes² (continued)

Drug (glucose-lowering dose)	Glucose-lowering efficacy ^{5,5b,5}	Impact on weight ^{2,5,5,7,5}	Hypoglycemia risk as monotherapy	Impact on comorbidities ^d	Cost ^{5b,5}	Common adverse effects ^{5b,5,5}	Practical considerations ^{5b}
Thiazolidinedione: Pioglitazone (15–45 mg orally daily)	High (1%–2%)	Gain	No	Atherosclerotic cardiovascular disease: likely benefit ^{8,7,5} Chronic kidney disease: neutral HF: increased risk	\$	Most common adverse effects: upper respiratory infection (13%), headache (9%), sinusitis (6%), myalgia (5%), pharyngitis (5%) Contraindications: New York Heart Association class III or IV HF, hypersensitivity Warnings/precautions: HF, liver toxicity, bladder cancer, fluid retention/edema, fractures, macular edema	When to use Add-on treatment in individuals who require high levels of HbA _{1c} lowering (1%–2% above target) Inexpensive, can be used when cost is a concern Dosing considerations ⁸² Benefits maximized and adverse effects minimized at doses of 15 or 30 mg Weight gain, edema, and heart failure risk higher at 45-mg dose Fracture risk similar across all doses

Abbreviations: GIP, glucose-dependent insulintropic polypeptide; GLP-1RA, glucagon-like peptide-1 receptor agonist; HFpEF, heart failure with preserved ejection fraction; HFREF, heart failure with reduced ejection fraction; SGLT, sodium-glucose cotransporter.

^a Commonly used classes of medications currently approved in the US for treatment of type 2 diabetes.

^b Based on mean hemoglobin A_{1c} (HbA_{1c}) reductions from baseline in clinical trials of drug-naïve patients with type 2 diabetes. Individualized glycemic responses vary based on starting HbA_{1c} and other patient factors.

^c Relative weight loss effect: modest, <5% loss from baseline; intermediate, 5%–10%; high, >10%.

^d Specific agents have evidence of benefit from dedicated outcome trials.

^e Rates listed are taken from the glimepiride package insert. Specific rates not provided for glyburide and glipizide.

^f From National Average Drug Acquisition Cost data. Based on the price of a 30-day supply at the maximum recommended dose. \$ = \$1100/mo; \$\$ = \$101–300/mo; \$\$\$ = \$301–600/mo; \$\$\$\$ = >\$600/mo.

^g Derived from product package insert; ranges for frequency of common adverse effects at highest indicated dose are provided by class unless otherwise indicated. Refer to product-specific labeling for specific rates.

^h Gastrointestinal adverse event rates across the range of doses for metformin include immediate release and extended-release products; extended-release products are associated with lower rates of diarrhea, nausea, and vomiting. Consider periodic screening for B12 deficiency.¹⁴

ⁱ Cardiovascular and kidney outcome trials are ongoing.

^j Gastrointestinal adverse event rates are for doses approved by the US Food and Drug Administration for glucose lowering. Higher doses for weight loss are associated with higher rates of nausea and vomiting.

^k Sotagliflozin is a SGLT/2 inhibitor indicated to reduce the risk of cardiovascular death, hospitalization for HF, and urgent HF visits in adults with HF or type 2 diabetes, CKD, and other cardiovascular risk factors; it is not currently indicated for glucose lowering in type 2 diabetes and thus not included.⁸³

Table 3. Factors for Individualized Selection of Insulin Therapy in People With Type 2 Diabetes^a

Drug class and agents ^b	Usual dosing range for glucose-lowering ^{5,9}	Glucose-lowering efficacy	Cost ^{5,8,c}	Safety/tolerability ^{5,9,d}	Considerations for dosing and titration ^{14,92}	Practical considerations
Basal insulin:						
Human NPH	Typically up to 200-300 units; above this, consider concentrated insulins ^a	In theory, no limit to HbA _{1c} lowering potential	\$ - \$\$\$	Most common adverse effects	Adding basal insulin: Start 10 units or 0.1-0.2 units/kg/d	When to use
Degludec			Human insulin (NPH, regular) is lower cost than analog insulins; follow-on and biosimilar insulins often lower cost than the reference insulin product	Hypoglycemia	Increase 2 units every 3 d until at FPG target without overnight or midday hypoglycemia	First-line treatment with severe hyperglycemic symptoms (ie, polyuria or polydipsia) and life-threatening hyperglycemic crisis (ie, diabetic ketoacidosis or hyperosmolar hyperglycemic state) and/or HbA _{1c} >10%
Glargine				Lipohypertrophy or lipatrophy	If not already on GLP-1RA or dual GLP-1/GIP RA, consider adding	Add-on treatment for individuals taking 1 or more oral glucose-lowering drugs at maximally tolerated doses who require injectable therapies to meet glycemic targets (ie, HbA _{1c} level more than 1.5%-2% above goal)
Glargine biosimilar (glargine-yfqn, glargine-agl) and follow-on products ^b				Weight gain		
Bolus insulin:				Contraindications:		
Human regular				Hypersensitivity		
Aspart				Warnings/precautions	Adding prandial insulin: Start with 4 units (or 10% of basal dose) to the largest meal of the day, titrate based on response, then add additional injections in step-wise manner to second and third meals	
Aspart biosimilar (aspart-szjj) ^b				Never share insulin delivery devices between patients, even if the needle is changed	Titrate by 1-2 units (10%-15%) twice weekly	
Fast-acting aspart				Increased risk of fluid retention/edema; risk increased further when used in combination with thiazolidinediones	Consider premixed insulin in people with meal patterns that match premixed insulin kinetics (eg, large breakfast and supper, small mid-day meal)	Basal insulin can be used to target elevated fasting glucose levels (ie, >80-130 mg/dl)
Lispro						Prandial insulin can be used to target elevated postprandial glucose levels within 1-2 h after meal (ie, >180 mg/dl)
Lispro biosimilar (lispro-aabc) and follow-on products ^b						Impact on key comorbidities:
Glulisine					Switching insulin formulations:	Neutral Cardiovascular ^{a3} and kidney effects
Inhaled insulin					If close to glycemic target: Sum the total daily dose of insulin and reduce by 10%, then titrate based on glucose monitoring	Hypoglycemia:
Premixed insulin:					If well above glycemic target, switch to the equivalent dose, then titrate	Analog insulins generally have less hypoglycemia than human insulins
Aspart 70/30					Anticipate total daily insulin dose reduction with treatment of glucose toxicity and resolution of insulin resistance as counter-regulatory hormone levels and volume depletion resolve	When to hold:
Lispro 75/25						If nothing per mouth, hold or reduce insulin by 50%-80% to weight-based basal requirement (eg, 0.2-0.3 units/kg ideal body weight)
Lispro 50/50						
NPH/regular 70/30						
Fixed dose combinations:						
Degludec/liraglutide						
Glargine/lixisenatide						

Abbreviations: FPG, fasting plasma glucose; GIP, glucose-dependent insulinotropic polypeptide; GLP-1RA, glucagon-like peptide-1 receptor agonist; kg, kilograms; NPH, neutral protamine Hagedorn; NPO, nothing per mouth.

^a Most insulins available on the market are U-100 concentration (U-100 = 100 units of insulin/mL solution). Concentrated insulins include U-200 insulin degludec or U-200 insulin lispro (U-200 = 200 units of insulin/mL solution), U-300 insulin glargine (U-300 = 300 units of insulin/mL solution), and U-500 regular insulin (U-500 = 500 units of insulin/mL solution). Concentrated insulins can be used to reduce injection volume in individuals on high insulin doses.

^b "Follow-on insulins" broadly refers to copies of an original insulin; "biosimilar insulin" is a specific type of follow-on insulin that has undergone rigorous testing to demonstrate it is highly similar to the reference insulin with no clinically meaningful differences in safety and effectiveness.

^c Cost information is derived from National Average Drug Acquisition Cost (NADAC) data. Cost ratings are based on the price of a 30-day (1-month) supply at the maximum recommended dose. \$ = \$1-100/mo; \$\$ = \$101-300/mo; \$\$\$ = \$301-600/mo; \$\$\$\$ = >\$600/mo.

^d Derived from product package insert information.

Table 4. Current Clinical Practice Recommendations for Management of Type 2 Diabetes From Major Professional Societies^a

Category	American Diabetes Association (2025) ¹⁴	American Association of Clinical Endocrinology (2023) ⁹⁴	Endocrine Society (older adults, 2019) ⁹⁵	American College of Physicians (2024) ^{96,97}	VA/DoD (US Veterans Affairs/Department of Defense) (2023) ⁹⁸	Diabetes Canada (2024) ⁹⁹	National Institute for Health and Care Excellence (UK) (2022) ¹⁰⁰	World Health Organization (2018) ¹⁰¹	International Diabetes Federation (2025) ¹⁰²
HbA _{1c} or glucose target for nonpregnant adults (general population)	<7% individualize <6.5% younger, short duration, if achieved safely <8% older, multiple comorbidities	≤6.5% or as close to normal as is safe and achievable for patients 7%-8% if high risk for hypoglycemia or limited life expectancy	<7.5 to <8.5% depending on health status; minimize hypoglycemia	7%-8%, deintensify if <6.5%	7%-8.5%, individualize	≤6.5% for adults if low risk of hypoglycemia 7.0%-8.0% most adults 7.1%-8.0% Functionally dependent 7.1%-8.5% Recurrent severe hypoglycemia Hypoglycemia unawareness Limited life expectancy Frail elderly and/or dementia	<7% on medication, individualize, maintain lower target if achieved without hypoglycemia	<7% when available, otherwise fasting blood glucose <126 mg/dL (individualize)	General target <7.0% Personalize HbA _{1c} target: higher in older adults and lower in those newly diagnosed If HbA _{1c} assay not available, use any available glucose measure
Healthy/lifestyle behaviors	Recommended	Recommended	Recommended	Recommended	Recommended	Recommended	Recommended	Recommended	Recommended
First-line medication	Metformin or other agents and combination therapies that provide adequate efficacy to attain HbA _{1c} goals. Use SGLT2i or GLP-1RA with cardiovascular or kidney benefit in the presence of those comorbidities ^b	Metformin in absence of cardiovascular or kidney comorbidities ^b Use SGLT2i or GLP-1RA with cardiovascular or kidney benefit in the presence of those comorbidities ^b	Metformin if tolerated in older adults	Metformin	Based on cardiovascular and kidney comorbidities, efficacy and risk-benefit ratio of each medication class	Metformin	Metformin	Metformin	Metformin In obese persons, consider metformin and GLP-1 RA (optimal care) or metformin and SGLT2i (basic care; SGLT2i available in many low- and middle-income countries at affordable cost)
Cardiovascular and kidney protective SGLT2i or GLP-1RA in those with ASCVD or high-risk ASCVD ^c	Recommended Independent of HbA _{1c}	Recommended Independent of HbA _{1c}	Recommended	Recommended And, add as next step after metformin for inadequate glycemic control (regardless of comorbidities)	Recommended Independent of HbA _{1c}	Recommended Independent of HbA _{1c}	Recommended ASCVD: SGLT2i High risk for ASCVD: consider SGLT2i	Recommended GLP-1 RA or SGLT2i (optimal care) SGLT2i (basic care) And, add as next step after metformin for inadequate glycemic control (regardless of comorbidities)	Recommended

(continued)

Table 4. Current Clinical Practice Recommendations for Management of Type 2 Diabetes From Major Professional Societies^a (continued)

Category	American Diabetes Association (2025) ¹⁴	American Association of Clinical Endocrinology (2023) ⁹⁴	Endocrine Society (older adults, 2019) ⁹⁵	American College of Physicians (2024) ^{96,97}	VA/DoD (US Veterans Affairs /Department of Defense) (2023) ⁹⁸	Diabetes Canada (2024) ⁹⁹	National Institute for Health and Care Excellence (UK) (2022) ¹⁰⁰	World Health Organization (2018) ¹⁰¹	International Diabetes Federation (2025) ¹⁰²
SGLT2i in those with HF or CKD ^c	Recommended Independent of HbA _{1c} Recommend SGLT2i or GLP-1RA with proven benefit in CKD SGLT2i preferred in HF	Recommended Independent of HbA _{1c} Recommend SGLT2i or GLP-1RA with proven benefit in CKD SGLT2i preferred in HF	Use insulin and sulfonylurea sparingly in older adults	Recommended Prioritize adding SGLT2i for CKD or HF	Recommended Independent of HbA _{1c} Recommend SGLT2i with proven benefit in CKD but can also consider GLP-1 RA SGLT2i preferred in HF	Recommended Independent of HbA _{1c} Recommend SGLT2i with proven benefit in CKD but can also consider GLP-1RA SGLT2i preferred in HF	Recommended HF: SGLT2i add to metformin CKD, use SGLT2i if receiving ACEi or ARB or UACR>30 mg/g	Cardiorenal: GLP-1 RA or SGLT2i (optimal care) Cardiorenal: SGLT2i (basic care) SGLT2i preferred in HF	
Combination SGLT2i and GLP-1RA in those with ASCVD or high ASCVD risk	If not at glycemic target	If not at glycemic target			Consider	If not at glycemic target			
When to initiate injectable therapy (ie, GLP-1RA, dual GLP-1/GIP RA, or insulin) to meet glycemic targets	GLP-1RA or dual GLP-1/GIP RA are preferred to insulin for persistent hyperglycemia as initial injectable Consider insulin initially with: Evidence of ongoing catabolism Symptomatic hyperglycemia HbA _{1c} >10% and/or glucose >300 mg/dL	If not at target at <3 mo, GLP-1RA as first injectable; if HbA _{1c} >10% and/or glucose >300 mg/L with symptomatic hyperglycemia, or not at glycemic target, use basal insulin with or without GLP-1RA	Use insulin and sulfonylurea sparingly in older adults	Do not add DPP-4i to metformin to reduce morbidity or all-cause mortality Discontinue insulin or sulfonylurea when possible; insulin and sulfonylurea are inferior to SGLT2i and GLP-1RA for morbidity and all-cause mortality but “may still have some limited value for glycemic control”	Strong comorbidity focus ^a Deprioritize insulin, sulfonylurea, and meglitinide especially >65 y	Strong comorbidity focus ^a Initial combination therapy with metformin and second agent if HbA _{1c} >1.5% above target	Ineffective dual oral therapy: Start NPH Use analogue insulin if hypoglycemia on NPH Start basal bolus or premixed insulin for HbA _{1c} ≥9% GLP-1RA for BMI ≥35 or <35 with comorbidities. Stop if HbA _{1c} reduction <1% and weight loss <3% in 6 mo	Start human insulin if goal not achieved on metformin and sulfonylurea; consider long-acting insulin analogues if frequent, severe hypoglycemia on human insulin Begin insulin therapy when optimized available glucose-lowering medications and lifestyle interventions do not maintain target blood glucose control Commence with single daily injection of basal analog or insulin (optimal care) or affordable human, analog, or biosimilar insulin (basic care)	
Additional recommendations	Strong weight and comorbidity focus ^b	Strong weight and comorbidity focus ^b Alternate algorithms for “complication-” or “glucose-” centric approaches; focus on rapid goal attainment GLP-1 RA or pioglitazone for stroke	Assess overall health and values to determine treatments and targets; simplify medication and relax targets with cognitive impairment	Do not add DPP-4i to metformin to reduce morbidity or all-cause mortality Discontinue insulin or sulfonylurea when possible; insulin and sulfonylurea are inferior to SGLT2i and GLP-1RA for morbidity and all-cause mortality but “may still have some limited value for glycemic control”	Strong comorbidity focus ^a Deprioritize insulin, sulfonylurea, and meglitinide especially >65 y	Strong comorbidity focus ^a Initial combination therapy with metformin and second agent if HbA _{1c} >1.5% above target	Second-line: DPP-4i or pioglitazone or sulfonylurea or SGLT2i	Target population is low-resource settings in low- or high-income countries Second line: sulfonylurea If insulin is unsuitable (after metformin and/or sulfonylurea), a DPP-4 inhibitor, SGLT-2i inhibitor, or a thiazolidinedione may be added	Describes 2 levels of standards of diabetes care: “optimal care” sets the standard for evidence based care which would ideally be universally available “basic care” aims to achieve the same objectives but is provided in a healthcare setting with limited resources
Abbreviations: DPP4i, DPP-4 inhibitor; NPH, neutral protamine Hagedorn insulin. Cells are blank if the topic is not explicitly addressed by the guideline. Comorbidities include atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and chronic kidney disease (CKD).									

Abbreviations: DPP-4i, DPP-4 inhibitor; NPH, neutral protamine Hagedorn insulin.

^a Cells are blank if the topic is not explicitly addressed by the guideline.^b Comorbidities include atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and chronic kidney disease (CKD).^c Medications with demonstrated cardiovascular or kidney benefit within each class are preferred when used for this indication. For SGLT2i, these include canagliflozin, dapagliflozin and empagliflozin. For GLP-1RA, these include dulaglutide, liraglutide, and semaglutide.

Heart Failure

Trials of HF outcomes with dapagliflozin and empagliflozin, enrolling up to 50% of participants with type 2 diabetes, report reduction in cardiovascular death and improvement of HF among patients with HF with reduced ejection fraction and HF with preserved ejection fraction, respectively, independent of diabetes status, compared with placebo.^{66-69,88} Recent trials of semaglutide and tirzepatide have also reported improved HF symptoms and function in patients with obesity-related HF with preserved ejection fraction compared with placebo.^{74,75,109}

Chronic Kidney Disease

SGLT2 inhibitors have beneficial effects on kidney outcomes including reduced progression to kidney failure, eGFR decline to less than 10 to 15 mL/min/1.73 m², decrease in eGFR of at least 40%, or death from kidney causes in trials that included people with type 2 diabetes and CKD.¹⁴ The first dedicated kidney outcome trial with a GLP-1RA (injectable semaglutide) demonstrated benefit in reducing major kidney disease events.¹¹⁰

Treatment Guidelines and Evidence

Numerous guidelines outline approaches to medical management of hyperglycemia in patients with type 2 diabetes.^{14,94-101} Many guidelines recommend an HbA_{1c} target of less than 6.5% or 7% for most nonpregnant adults that is individualized based on patient-related factors, with higher targets (<7.5%-8.5%) for older adults and those with high risk of hypoglycemia or limited life expectancy (Table 4).^{14,95,96,102,111} Current guidelines recommend specific SGLT2i agents that improve atherosclerotic cardiovascular disease, HF, CKD, or mortality outcomes and GLP-1RAs that improve atherosclerotic cardiovascular disease, CKD, or mortality outcomes in individuals who have these conditions or are at high cardiovascular risk.^{14,94,97-100} Many evidence-based guidelines continue to recommend metformin as first-line treatment,^{94-97,99-102} particularly in patients without cardiovascular or kidney comorbidities, although some guidelines no longer state that metformin be used prior to using GLP-1RAs or SGLT2is in patients with atherosclerotic cardiovascular disease, HF, or CKD.^{14,94,98} Some guidelines recommend combination SGLT2i and GLP-1RA in patients with type 2 diabetes and cardiovascular disease or those at high risk of CVD if glycemic targets are not met (Table 4). Studies have been limited by small sample sizes in combination therapy subgroups and trials have not consistently shown benefit for the combination of SGLT2is and GLP-1RAs on cardiovascular and kidney outcomes.^{73,112}

The major disadvantage of SGLT2is, GLP-1RAs, and dual GIP/GLP-1RAs, aside from their specific adverse effects (Table 2), is limited access in the US due to high cost for individuals without insurance or with high-deductible health plans.¹¹³ Strategies such as co-payment cards, manufacturer patient assistance programs, and the Medicare low-income subsidy may help patients navigate high prescription drug costs.¹¹⁴ Generic formulations of liraglutide and dapagliflozin have been approved in the US, but are not widely available.

Intensification of Therapy

Type 2 diabetes is a progressive disease and combination pharmacotherapy is often required in a stepwise manner to maintain HbA_{1c} goals.

When intensifying the glucose-lowering regimen, it is important to consider other drug- and patient-specific factors (Table 2).^{91,115} When making decisions about additional therapy, a patient-centered approach that addresses patient priorities and preferences while establishing attainable goals is beneficial.^{14,116,117} Although many patients with type 2 diabetes eventually require insulin due to progressive hyperglycemia, insulin may be associated with hypoglycemia. The risk of hypoglycemia is highest in patients taking insulin or secretagogues (ie, sulfonylureas or meglitinides; Table 2) who are 75 years or older or have cognitive impairment, CKD, or insulin deficiency.¹¹⁸⁻¹²⁰ In a population-based study of 1.66 million people filling at least 1 glucose-lowering medication prescription, the rate of severe hypoglycemia per 100 person-years was 2.3 for people 75 years and older, 1.3 for those aged 64 to 75 years, and 0.9 for younger ages.¹²¹ Sulfonylureas are inexpensive and have high HbA_{1c}-lowering efficacy.^{38,81} Reducing the risk of hypoglycemia with sulfonylureas can be achieved by only taking the medication when eating and using the lowest effective doses. For those at higher risk of hypoglycemia, long-acting glyburide should be avoided, and all other sulfonylureas should be used cautiously.^{55,56,59,92} In patients already treated with insulin and/or insulin secretagogues such as sulfonylureas or meglitinides (Table 3) for whom addition of a SGLT2i or GLP-1RA is indicated, deintensification (dose reduction or discontinuation) of existing therapy may be considered to minimize hypoglycemia risk.^{14,122}

Metabolic Surgery

Metabolic (bariatric) surgery referral may be considered in people with type 2 diabetes who have a body mass index greater than or equal to 30.0 (or greater than or equal to 27.5 in Asian individuals), especially in the presence of other obesity-related comorbidities such as hypertension or dyslipidemia. In addition to weight reduction and decreased glycemia (with diabetes remission in some patients), expected benefits of metabolic surgery include improved quality of life, reduced cardiovascular events, and decreased risk of hepatocellular, colorectal, pancreatic, gallbladder, breast, endometrial, and ovarian cancers.^{14,123-126}

Practical Considerations

Patients with type 2 diabetes are commonly treated by primary care clinicians. HbA_{1c} should be assessed at least every 6 months or every 3 months for patients not meeting their glycemic targets or for those with recent glucose-lowering medication dose adjustments. Referrals to a diabetes care and education specialist for diabetes self-management education and to a registered dietitian for medical nutrition therapy are recommended for all individuals with type 2 diabetes.¹⁴ Most adults with type 2 diabetes should be counseled to engage in moderate- to vigorous-intensity aerobic physical activity such as brisk walking, swimming, or running (≥150 minutes/week) and resistance exercise (2-3 sessions/week). Patients should be counseled to lose weight or maintain weight if weight loss is not advisable. Multidrug regimens, complicated insulin regimens (ie, multiple daily injections), high-dose insulin (ie, >200 units/d), and consideration of use of diabetes technology (such as CGMs or insulin pumps) may warrant consultation with endocrinology. Lack of expected response to treatment or persistent hyperglycemia in patients with new-onset diabetes who are adherent to metformin or other oral glucose-lowering therapy should prompt screening for type 1 diabetes with islet autoantibodies (eg, glutamic acid

decarboxylase) or other types of diabetes (Table 1) and may necessitate endocrine referral.

Limitations

This review has several limitations. First, it is not a systematic review, and the quality of included literature was not formally evaluated. Second, relevant articles may have been missed. Third, randomized clinical trials investigating cardiovascular outcomes did not generally include individuals at lower risk of cardiovascular disease. Fourth, clinical trials of newer glucose-lowering drugs such as SGLT2is and GLP1RAs were of relatively short duration, and long-term effects of these medications are currently unknown.

Conclusions

Type 2 diabetes affects up to 14% of the global population and is associated with preventable long-term complications such as cardiovascular disease, kidney failure, vision loss and increased mortality. In addition to lifestyle modifications including diet, exercise and weight management, metformin is generally first-line therapy for attainment of HbA_{1c} targets. For individuals with type 2 diabetes and cardiovascular or kidney disease or at high cardiovascular risk, guidelines recommend early treatment with SGLT2i and/or GLP-1RA medications.

ARTICLE INFORMATION

Accepted for Publication: April 4, 2025.

Published Online: June 23, 2025.
doi:10.1001/jama.2025.5956

Author Contributions: Dr Kalyani had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Conflict of Interest Disclosures: Dr Kalyani reported serving as a member of the National Board of Directors and President of Medicine and Science of the American Diabetes Association. Dr Neumiller reported receiving personal fees from Bayer, Proteomics International, PowerPak, and Med Learning Group outside the submitted work and serving as a member of the board of directors of the American Diabetes Association. Dr Maruthur reported receiving grants from Maryland Health Services outside the submitted work. Dr Wexler reported serving on data monitoring committees for Novo Nordisk for trials concluding in 2024 outside the submitted work.

Submissions: We encourage authors to submit papers for consideration as a Review. Please contact Kristin Walter, MD, at kristin.walter@jamanetwork.org.

REFERENCES

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022. *Lancet*. 2024;404(10467):2077-2093. doi:10.1016/S0140-6736(24)02317-1
2. International Diabetes Federation. *IDF Diabetes Atlas, 11th edition*. Accessed April 30, 2025. https://diabetesatlas.org/media/uploads/sites/3/2025/04/IDF_Atlas_11th_Edition_2025.pdf
3. Centers for Disease Control and Prevention. *National Diabetes Statistics Report 2024*. Department of Health and Human Services; 2024. Accessed February 23, 2025. <https://www.cdc.gov/diabetes/php/data-research/index.html>
4. Gwira JA, Fryar CD, Gu Q. Prevalence of total, diagnosed, and undiagnosed diabetes in adults: United States, August 2021-August 2023. *NCHS Data Brief*. 2024;516(516):CS354814. doi:10.15620/cdc/165794
5. Wysham C, Shubrook J. Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications. *Postgrad Med*. 2020;132(8):676-686. doi:10.1080/00325481.2020.1771047
6. Magliano DJ, Islam RM, Barr ELM, et al. Trends in incidence of total or type 2 diabetes: systematic review. *BMJ*. 2019;366:l5003. doi:10.1136/bmj.l5003
7. Global Burden of Disease Study 2021: results. Institute for Health Metrics Evaluation. Accessed February 23, 2025. <https://vizhub.healthdata.org/gbd-results/>
8. Echouffo-Tcheugui JB, Perreault L, Ji L, Dagogo-Jack S. Diagnosis and management of prediabetes: a review. *JAMA*. 2023;329(14):1206-1216. doi:10.1001/jama.2023.4063
9. Moonesinghe R, Beckles GLA, Liu T, Khoury MJ. The contribution of family history to the burden of diagnosed diabetes, undiagnosed diabetes, and prediabetes in the United States: analysis of the National Health and Nutrition Examination Survey, 2009-2014. *Genet Med*. 2018;20(10):1159-1166. doi:10.1038/gim.2017.238
10. Jayedi A, Soltani S, Motlagh SZ, et al. Anthropometric and adiposity indicators and risk of type 2 diabetes. *BMJ*. 2022;376:e067516. doi:10.1136/bmj-2021-067516
11. Cheng YJ, Kanaya AM, Araneta MRG, et al. Prevalence of diabetes by race and ethnicity in the United States, 2011-2016. *JAMA*. 2019;322(24):2389-2398. doi:10.1001/jama.2019.19365
12. Aune D, Norat T, Leitzmann M, Tonstad S, Vatten LJ. Physical activity and the risk of type 2 diabetes. *Eur J Epidemiol*. 2015;30(7):529-542. doi:10.1007/s10654-015-0056-z
13. Juan J, Sun Y, Wei Y, et al. Progression to type 2 diabetes mellitus after gestational diabetes mellitus diagnosed by IADPSG criteria: systematic review and meta-analysis. *Front Endocrinol (Lausanne)*. 2022;13:1012244. doi:10.3389/fendo.2022.1012244
14. American Diabetes Association Professional Practice Committee. Standards of care in diabetes: 2025. *Diabetes Care*. 2025;48(1)(suppl 1):S1-S5. doi:10.2337/dc25-SINT
15. Suzuki K, Hatzikotoulas K, Southam L, et al; VA Million Veteran Program. Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. *Nature*. 2024;627(8003):347-357. doi:10.1038/s41586-024-07019-6
16. Meigs JB. The genetic epidemiology of type 2 diabetes: opportunities for health translation. *Curr Diab Rep*. 2019;19(8):62. doi:10.1007/s11892-019-1173-y
17. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes. *Cardiovasc Diabetol*. 2018;17(1):83. doi:10.1186/s12933-018-0728-6
18. Diabetes. Centers for Disease Control and Prevention National Center for Health Statistics. Accessed February 23, 2025. <https://www.cdc.gov/nchs/fastats/diabetes.htm>
19. Younossi ZM, Golabi P, Price JK, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. *Clin Gastroenterol Hepatol*. 2024;22(10):1999-2010.e8. doi:10.1016/j.cgh.2024.03.006
20. Casagrande SS, Menke A, et al, eds. *Diabetes in America*. 3rd ed. 2018.
21. Pearson-Stuttard J, Buckley J, Cicek M, Gregg EW. The changing nature of mortality and morbidity in patients with diabetes. *Endocrinol Metab Clin North Am*. 2021;50(3):357-368. doi:10.1016/j.ecl.2021.05.001
22. US Preventive Services Task Force. Screening for prediabetes and type 2 diabetes: US Preventive Services Task Force recommendation statement. *JAMA*. 2021;326(8):736-743. doi:10.1001/jama.2021.12531
23. *Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus*. World Health Organization; 1999. Accessed February 23, 2025. https://iris.who.int/bitstream/handle/10665/70523/WHO_NMH_CHP_CPM_11.1_eng.pdf
24. Thomas NJ, Lynam AL, Hill AV, et al. Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes. *Diabetologia*. 2019;62(7):1167-1172. doi:10.1007/s00125-019-4863-8
25. Sainsbury E, Kizirian NV, Partridge SR, et al. Effect of dietary carbohydrate restriction on glycemic control in adults with diabetes. *Diabetes Res Clin Pract*. 2018;139:239-252. doi:10.1016/j.diabres.2018.02.026
26. Zheng X, Zhang W, Wan X, et al. The effects of Mediterranean diet on cardiovascular risk factors, glycemic control and weight loss in patients with type 2 diabetes: a meta-analysis. *BMC Nutr*. 2024;10(1):59. doi:10.1186/s40795-024-00836-y
27. Chiavaroli L, Vigiouliouk E, Nishi SK, et al. DASH dietary pattern and cardiometabolic outcomes: an umbrella review of systematic reviews and meta-analyses. *Nutrients*. 2019;11(2):338. doi:10.3390/nu11020338
28. Estruch R, Ros E, Salas-Salvado J, et al; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. *N Engl J Med*. 2018;378(25):e34. doi:10.1056/NEJMoa1800389

29. Franz MJ, MacLeod J, Evert A, et al. Academy of Nutrition and Dietetics Nutrition Practice guideline for type 1 and type 2 diabetes in adults. *J Acad Nutr Diet*. 2017;117(10):1659-1679. doi:10.1016/j.jand.2017.03.022
30. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. *Diabetes Care*. 2019;42(5):731-754. doi:10.2337/dci19-0014
31. Davis J, Fischl AH, Beck J, et al. 2022 National standards for diabetes self-management education and support. *Diabetes Care*. 2022;45(2):484-494. doi:10.2337/dc21-2396
32. Bekele BB, Negash S, Bogale B, et al. Effect of diabetes self-management education (DSME) on glycated hemoglobin (HbA1c) level among patients with T2DM. *Diabetes Metab Syndr*. 2021;15(1):177-185. doi:10.1016/j.dsx.2020.12.030
33. Gallardo-Gómez D, Salazar-Martínez E, Alfonso-Rosa RM, et al. Optimal dose and type of physical activity to improve glycemic control in people diagnosed with type 2 diabetes: a systematic review and meta-analysis. *Diabetes Care*. 2024;47(2):295-303. doi:10.2337/dc23-0800
34. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. *Lancet*. 2018;391(10120):541-551. doi:10.1016/S0140-6736(17)33102-1
35. Wing RR; Look AHEAD Research Group. Does lifestyle intervention improve health of adults with overweight/obesity and type 2 diabetes? findings from the Look AHEAD randomized trial. *Obesity (Silver Spring)*. 2021;29(8):1246-1258. doi:10.1002/oby.23158
36. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*. 1998;352(9131):837-853. doi:10.1016/S0140-6736(98)07019-6
37. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet*. 1998;352(9131):854-865. doi:10.1016/S0140-6736(98)07037-8
38. Adler AI, Coleman RL, Leal J, Whiteley WN, Clarke P, Holman RR. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). *Lancet*. 2024;404(10448):145-155. doi:10.1016/S0140-6736(24)00537-3
39. Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med*. 2008;358(24):2545-2559. doi:10.1056/NEJMoa0802743
40. Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2008;358(24):2560-2572. doi:10.1056/NEJMoa0802987
41. Duckworth W, Abraira C, Moritz T, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med*. 2009;360(2):129-139. doi:10.1056/NEJMoa0808431
42. Chew EY, Ambrosius WT, Davis MD, et al; ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. *N Engl J Med*. 2010;363(3):233-244. doi:10.1056/NEJMoa1001288
43. Park L, Wexler D. Update in diabetes and cardiovascular disease: synthesizing the evidence from recent trials of glycemic control to prevent cardiovascular disease. *Curr Opin Lipidol*. 2010;21(1):8-14. doi:10.1097/MOL.0b013e328332dfaa
44. Reaven PD, Emanuele NV, Wiitala WL, et al; VADT Investigators. Intensive glucose control in patients with type 2 diabetes - 15-year follow-up. *N Engl J Med*. 2019;380(23):2215-2224. doi:10.1056/NEJMoa1806802
45. Crabtree T, Ogender JJ, Vinogradova Y, Gordon J, Idris I. Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age ≥ 60 years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies. *Expert Rev Endocrinol Metab*. 2022;17(3):255-267. doi:10.1080/17446651.2022.2079495
46. Moffet HH, Huang ES, Liu JY, et al. Severe hypoglycemia and falls in older adults with diabetes: The Diabetes & Aging Study. *Diabet Epidemiol Manag*. 2023;12:100162. doi:10.1016/j.deman.2023.100162
47. Young LA, Buse JB, Weaver MA, et al; Monitor Trial Group. Glucose self-monitoring in non-insulin-treated patients with type 2 diabetes in primary care settings: a randomized trial. *JAMA Intern Med*. 2017;177(7):920-929. doi:10.1001/jamainternmed.2017.1233
48. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. *Diabetologia*. 2008;51(3):408-416. doi:10.1007/s00125-007-0911-x
49. Jancev M, Vissers TACM, Visseren FLJ, et al. Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis. *Diabetologia*. 2024;67(5):798-810. doi:10.1007/s00125-024-06107-6
50. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes. *Diabetes Ther*. 2017;8(1):55-73. doi:10.1007/s13300-016-0223-6
51. Garg SK, Kipnes M, Castorino K, et al. Accuracy and safety of Dexcom G7 continuous glucose monitoring in adults with diabetes. *Diabetes Technol Ther*. 2022;24(6):373-380. doi:10.1089/dia.2022.0011
52. Peters AL, Ahmann AJ, Battelino T, et al. Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2016;101(11):3922-3937. doi:10.1210/jc.2016-2534
53. Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology clinical practice guideline. *Endocr Pract*. 2021;27(6):505-537. doi:10.1016/j.epr.2021.04.008
54. Taylor SI, Yazdi ZS, Beitelshes AL. Pharmacological treatment of hyperglycemia in type 2 diabetes. *J Clin Invest*. 2021;131(2):e142243. doi:10.1172/JCI142243
55. Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. *Ann Intern Med*. 2020;173(4):278-286. doi:10.7326/M20-0864
56. Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. *Diabetologia*. 2022;65(8):1251-1261. doi:10.1007/s00125-022-05715-4
57. Tsapas A, Karagiannis T, Kakotrichi P, et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. *Diabetes Obes Metab*. 2021;23(9):2116-2124. doi:10.1111/dom.14451
58. NADAC (National Average Drug Acquisition Cost). Data.Medicare.gov. Accessed February 23, 2025. <https://data.medicare.gov/dataset/99315a95-37ac-4eee-946a-3c523b4c481e>
59. Micromedex. Accessed February 23, 2025. <https://www.micromedexsolutions.com>
60. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med*. 2008;359(15):1577-1589. doi:10.1056/NEJMoa0806470
61. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*. 2017;377(7):644-657. doi:10.1056/NEJMoa1611925
62. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720
63. Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med*. 2019;380(24):2295-2306. doi:10.1056/NEJMoa1811744
64. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. *N Engl J Med*. 2020;383(15):1436-1446. doi:10.1056/NEJMoa2024816
65. Herrington WG, Staplin N, Wanner C, et al; The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. *N Engl J Med*. 2023;388(2):117-127. doi:10.1056/NEJMoa2204233
66. McMurray JJV, Solomon SD, Inzucchi SE, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med*. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303
67. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med*. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190
68. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med*. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038

69. Solomon SD, McMurray JJV, Claggett B, et al; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. *N Engl J Med*. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286
70. Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet*. 2019;394(10193):121-130. doi:10.1016/S0140-6736(19)31149-3
71. Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375(4):311-322. doi:10.1056/NEJMoa1603827
72. Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141
73. Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. *N Engl J Med*. 2024;391(2):109-121. doi:10.1056/NEJMoa2403347
74. Kosiborod MN, Petrie MC, Borlaug BA, et al; STEP-HFpEF DM Trial Committees and Investigators. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. *N Engl J Med*. 2024;390(15):1394-1407. doi:10.1056/NEJMoa2313917
75. Butler J, Shah SJ, Petrie MC, et al; STEP-HFpEF Trial Committees and Investigators. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. *Lancet*. 2024;403(10437):1635-1648. doi:10.1016/S0140-6736(24)00469-0
76. Almandoz JP, Lingvay I, Morales J, Campos C. Switching between glucagon-like peptide-1 receptor agonists: rationale and practical guidance. *Clin Diabetes*. 2020;38(4):390-402. doi:10.2337/cd19-0100
77. Scirica BM, Bhatt DL, Braunwald E, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med*. 2013;369(14):1317-1326. doi:10.1056/NEJMoa1307684
78. Dormandy JA, Charbonnel B, Eckland DJ, et al; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. *Lancet*. 2005;366(9493):1279-1289. doi:10.1016/S0140-6736(05)67528-9
79. Kernan WN, Viscoli CM, Furie KL, et al; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. *N Engl J Med*. 2016;374(14):1321-1331. doi:10.1056/NEJMoa1506930
80. Friás JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. *N Engl J Med*. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519
81. Rosenstock J, Kahn SE, Johansen OE, et al; CAROLINA Investigators. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. *JAMA*. 2019;322(12):1155-1166. doi:10.1001/jama.2019.13772
82. Spence JD, Viscoli C, Kernan WN, et al. Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance. *Diabetes Obes Metab*. 2022;24(6):1150-1158. doi:10.1111/dom.14687
83. Avgerinos I, Karagiannis T, Kakotrichi P, et al. Sotagliflozin for patients with type 2 diabetes: a systematic review and meta-analysis. *Diabetes Obes Metab*. 2022;24(1):106-114. doi:10.1111/dom.14555
84. Choi JG, Winn AN, Skandari MR, et al. First-Line therapy for type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a cost-effectiveness study. *Ann Intern Med*. 2022;175(10):1392-1400. doi:10.7326/M21-2941
85. Holman RR, Coleman RL, Chan JCN, et al; ACE Study Group. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol*. 2017;5(11):877-886. doi:10.1016/S2213-8587(17)30309-1
86. McGuire DK, Marx N, Mulvagh SL, et al; SOUL Study Group. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. *N Engl J Med*. Published online March 29, 2025. doi:10.1056/NEJMoa2501006
87. Holman RR, Haffner SM, McMurray JJ, et al; NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. *N Engl J Med*. 2010;362(16):1463-1476. doi:10.1056/NEJMoa1001122
88. Wiviott SD, Raz I, Bonaca MP, et al; DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2019;380(4):347-357. doi:10.1056/NEJMoa1812389
89. Silverii GA. Optimizing metformin therapy in practice: tailoring therapy in specific patient groups to improve tolerability, efficacy and outcomes. *Diabetes Obes Metab*. 2024;26(suppl 3):42-54. doi:10.1111/dom.15749
90. Aiken C, Tarry-Adkins J, Grant I, Reynolds R, Ozanne S. An update to the article "efficacy and side effect profile of different formulations of metformin: a systematic review and meta-analysis". *Diabetes Ther*. 2021;12(11):2813-2816. doi:10.1007/s13300-021-01155-2
91. Nathan DM, Lachin JM, Balasubramanyam A, et al; GRADE Study Research Group. Glycemia reduction in type 2 diabetes: glycemic outcomes. *N Engl J Med*. 2022;387(12):1063-1074. doi:10.1056/NEJMoa2200433
92. *Practical Insulin: A Handbook or Prescribing Providers*. 6th ed. American Diabetes Association; 2023.
93. Gerstein HC, Bosch J, Dagenais GR, et al; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med*. 2012;367(4):319-328. doi:10.1056/NEJMoa1203858
94. Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm: 2023 update. *Endocr Pract*. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001
95. LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2019;104(5):1520-1574. doi:10.1210/je.2019-00198
96. Qaseem A, Wilt TJ, Kansagara D, et al; Clinical Guidelines Committee of the American College of Physicians. Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians. *Ann Intern Med*. 2018;168(8):569-576. doi:10.7326/M17-0939
97. Qaseem A, Obley AJ, Shamlan T, et al; Clinical Guidelines Committee of the American College of Physicians. Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline from the American College of Physicians. *Ann Intern Med*. 2024;177(5):658-666. doi:10.7326/M23-2788
98. VA/DoD Clinical Practice Guideline for the Management of Type 2 Diabetes Mellitus. Department of Veterans Affairs, Department of Defense; 2023. Accessed February 23, 2025. https://www.healthquality.va.gov/guidelines/CD/diabetes/VAoD-Diabetes-CPG_Final_508.pdf
99. Clinical practice guidelines. Diabetes Canada. Accessed February 23, 2025. <https://guidelines.diabetes.ca/cpg>
100. Type 2 diabetes in adults: management. National Institute for Health and Care Excellence. Accessed February 23, 2025. <http://www.nice.org.uk/guidance/ng28>
101. Roglic G, Norris SL. Medicines for treatment intensification in type 2 diabetes and type of insulin in type 1 and type 2 diabetes in low-resource settings: synopsis of the World Health Organization guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in nonpregnant adults with diabetes mellitus. *Ann Intern Med*. 2018;169(6):394-397. doi:10.7326/M18-1149
102. Ceriello A, Colagiuri S. IDF global clinical practice recommendations for managing type 2 diabetes: 2025. *Diabetes Res Clin Pract*. Published online April 7, 2025. doi:10.1016/j.diabres.2025.112152
103. Centers for Disease Control and Prevention. United States Diabetes Surveillance System (USDSS). Accessed February 25, 2025. <https://gis.cdc.gov/grasp/diabetes/diabetesatlas-surveillance.html>
104. Kudva YC, Raghinaru D, Lum JW, et al; 2IQP Study Group. A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes. *N Engl J Med*. Published online May 8, 2025. doi:10.1056/NEJMoa2415948
105. de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int*. 2022;102(5):974-989. doi:10.1016/j.kint.2022.08.012
106. Kalyani RR. Glucose-lowering drugs to reduce cardiovascular risk in type 2 diabetes. *N Engl J Med*. 2021;384(13):1248-1260. doi:10.1056/NEJMc2000280

107. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. *JAMA Cardiol.* 2021;6(2):148-158. doi:10.1001/jamacardio.2020.4511
108. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes. *Lancet Diabetes Endocrinol.* 2019;7(10):776-785. doi:10.1016/S2213-8587(19)30249-9
109. Packer M, Zile MR, Kramer CM, et al; SUMMIT Trial Study Group. Tirzepatide for heart failure with preserved ejection fraction and obesity. *N Engl J Med.* 2025;392(5):427-437. doi:10.1056/NEJMoa2410027
110. Limonte CP, Pilla SJ, de Boer IH. Diabetes and chronic kidney disease. *JAMA.* 2024;333(4):343-344. doi:10.1001/jama.2024.24671
111. Munshi M, Neumiller JJ. Liberalisation, deintensification, and simplification in diabetes management: words matter. *Lancet Diabetes Endocrinol.* 2020;8(2):95-97. doi:10.1016/S2213-8587(19)30379-1
112. Apperloo EM, Neuen BL, Fletcher RA, et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists. *Lancet Diabetes Endocrinol.* 2024;12(8):545-557. doi:10.1016/S2213-8587(24)00155-4
113. DeJong C, Masuda C, Chen R, Kazi DS, Dudley RA, Tseng CW. Out-of-pocket costs for novel guideline-directed diabetes therapies under Medicare Part D. *JAMA Intern Med.* 2020;180(12):1696-1699. doi:10.1001/jamainternmed.2020.2922
114. Lalani HS, Hwang CS, Kesselheim AS, Rome BN. Strategies to help patients navigate high prescription drug costs. *JAMA.* 2024;332(20):1741-1749. doi:10.1001/jama.2024.17275
115. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. *JAMA.* 1999;281(21):2005-2012. doi:10.1001/jama.281.21.2005
116. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2022;45(11):2753-2786. doi:10.2337/dc22-0034
117. Kalyani RR, Allende-Vigo MZ, Antinori-Lent KJ, et al. Prioritizing patient experiences in the management of diabetes and its complications: an Endocrine Society position statement. *J Clin Endocrinol Metab.* 2024;109(5):1155-1178. doi:10.1210/clinem/dgad745
118. McCoy RG, Herrin J, Lipska KJ, Shah ND. Recurrent hospitalizations for severe hypoglycemia and hyperglycemia among US adults with diabetes. *J Diabetes Complications.* 2018;32(7):693-701. doi:10.1016/j.jdiacomp.2018.04.007
119. Pilemann-Lyberg S, Thorsteinsson B, Snorgaard O, et al. Severe hypoglycaemia during treatment with sulphonylureas in patients with type 2 diabetes in the Capital Region of Denmark. *Diabetes Res Clin Pract.* 2015;110(2):202-207. doi:10.1016/j.diabres.2015.09.006
120. McCoy RG, Lipska KJ, Yao X, Ross JS, Montori VM, Shah ND. Intensive treatment and severe hypoglycemia among adults with type 2 diabetes. *JAMA Intern Med.* 2016;176(7):969-978. doi:10.1001/jamainternmed.2016.2275
121. Lipska KJ, Yao X, Herrin J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006-2013. *Diabetes Care.* 2017;40(4):468-475. doi:10.2337/dc16-0985
122. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. *Kidney Int.* 2022;102(5S):S1-S127. doi:10.1016/j.kint.2022.06.008
123. Schauer PR, Bhatt DL, Kirwan JP, et al; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes. *N Engl J Med.* 2017;376(7):641-651. doi:10.1056/NEJMoa1600869
124. Courcoulas AP, Patti ME, Hu B, et al. Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes. *JAMA.* 2024;331(8):654-664. doi:10.1001/jama.2024.0318
125. Sjöholm K, Carlsson LMS, Svensson PA, et al. Association of bariatric surgery with cancer incidence in patients with obesity and diabetes. *Diabetes Care.* 2022;45(2):444-450. doi:10.2337/dc21-1335
126. Wilson RB, Lathigara D, Kaushal D. Systematic review and meta-analysis of the impact of bariatric surgery on future cancer risk. *Int J Mol Sci.* 2023;24(7):6192. doi:10.3390/ijms24076192